THIS IS WHAT HE HAD TO SAY.
Quote:
--------------------------------------------------------------------------------
We have no idea why our stock is under such a large amount of pressure lately and can only speculate as to the cause. Like yourself we find it very frustrating, particularly as nothing at all has changed at YM to cause this. We remain enthusiastic for the prospects of our lead drug CYT387, for which we will present updated data at the ASH conference on Dec 12.
Regards,
James
--------------------------------------------------------------------------------
James Smith, M.Sc.(Eng)
VP Corporate Communications
YM BioSciences Inc.
5045 Orbitor Drive
Building 11, Suite 400
Mississauga, Ontario L4W 4Y4
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM